Skip to main content
Top
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Multiple Myeloma | Primary research

Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis

Authors: Yue Peng, Dong Wu, Fangmei Li, Peihua Zhang, Yuandong Feng, Aili He

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Multiple Myeloma (MM) is a hematologic malignant disease whose underlying molecular mechanism has not yet fully understood. Generally, cell adhesion plays an important role in MM progression. In our work, we intended to identify key genes involved in cell adhesion in MM.

Methods

First, we identified differentially expressed genes (DEGs) from the mRNA expression profiles of GSE6477 dataset using GEO2R with cut-off criterion of p < 0.05 and [logFC] ≥ 1. Then, GO and KEGG analysis were performed to explore the main function of DEGs. Moreover, we screened hub genes from the protein–protein interaction (PPI) network analysis and evaluated their prognostic and diagnostic values by the PrognoScan database and ROC curves. Additionally, a comprehensive analysis including clinical correlation analysis, GSEA and transcription factor (TF) prediction, pan-cancer analysis of candidate genes was performed using both clinical data and mRNA expression data.

Results

First of all, 1383 DEGs were identified. Functional and pathway enrichment analysis suggested that many DEGs were enriched in cell adhesion. 180 overlapped genes were screened out between the DEGs and genes in GO terms of cell adhesion. Furthermore, 12 genes were identified as hub genes based on a PPI network analysis. ROC curve analysis demonstrated that ITGAM, ITGB2, ITGA5, ITGB5, CDH1, IL4, ITGA9, and LAMB1 were valuable biomarkers for the diagnosis of MM. Further study demonstrated that ITGA9 and LAMB1 revealed prognostic values and clinical correlation in MM patients. GSEA and transcription factor (TF) prediction suggested that MYC may bind to ITGA9 and repress its expression and HIF-1 may bind to LAMB1 to promote its expression in MM. Additionally, pan-cancer analysis showed abnormal expression and clinical outcome associations of LAMB1 and ITGA9 in multiple cancers.

Conclusion

In conclusion, ITGA9 and LAMB1 were identified as potent biomarkers associated with cell adhesion in MM.
Literature
1.
go back to reference Chng WJ, et al. Targeted therapy in multiple myeloma. Cancer Control. 2005;12(2):91–104.CrossRef Chng WJ, et al. Targeted therapy in multiple myeloma. Cancer Control. 2005;12(2):91–104.CrossRef
2.
go back to reference Robak P, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208.CrossRef Robak P, et al. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199–208.CrossRef
3.
go back to reference Leleu X. New hope for relapsed and refractory multiple myeloma. Lancet Oncol. 2013;14(11):1028–9.CrossRef Leleu X. New hope for relapsed and refractory multiple myeloma. Lancet Oncol. 2013;14(11):1028–9.CrossRef
4.
go back to reference Neri P, Bahlis NJ. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets. 2012;12(7):776–96.CrossRef Neri P, Bahlis NJ. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets. 2012;12(7):776–96.CrossRef
5.
go back to reference Katz BZ. Adhesion molecules–The lifelines of multiple myeloma cells. Semin Cancer Biol. 2010;20(3):186–95.CrossRef Katz BZ. Adhesion molecules–The lifelines of multiple myeloma cells. Semin Cancer Biol. 2010;20(3):186–95.CrossRef
6.
go back to reference Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11–25.CrossRef Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11–25.CrossRef
7.
go back to reference Seguin L, et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25(4):234–40.CrossRef Seguin L, et al. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25(4):234–40.CrossRef
8.
go back to reference Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.CrossRef Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22.CrossRef
9.
go back to reference Hoye AM, et al. The newcomer in the integrin family: integrin alpha9 in biology and cancer. Adv Biol Regul. 2012;52(2):326–39.CrossRef Hoye AM, et al. The newcomer in the integrin family: integrin alpha9 in biology and cancer. Adv Biol Regul. 2012;52(2):326–39.CrossRef
10.
go back to reference Allen MD, et al. Clinical and functional significance of alpha9beta1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol. 2011;223(5):646–58.CrossRef Allen MD, et al. Clinical and functional significance of alpha9beta1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol. 2011;223(5):646–58.CrossRef
11.
go back to reference Zhang J, et al. MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma. Tumour Biol. 2016;37(5):5941–9.CrossRef Zhang J, et al. MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma. Tumour Biol. 2016;37(5):5941–9.CrossRef
12.
go back to reference Hibi K, et al. Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer. Oncogene. 1994;9(2):611–9.PubMed Hibi K, et al. Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer. Oncogene. 1994;9(2):611–9.PubMed
13.
14.
go back to reference Burgeson RE, et al. A new nomenclature for the laminins. Matrix Biol. 1994;14(3):209–11.CrossRef Burgeson RE, et al. A new nomenclature for the laminins. Matrix Biol. 1994;14(3):209–11.CrossRef
15.
go back to reference Ryan MC, et al. The functions of laminins: lessons from in vivo studies. Matrix Biol. 1996;15(6):369–81.CrossRef Ryan MC, et al. The functions of laminins: lessons from in vivo studies. Matrix Biol. 1996;15(6):369–81.CrossRef
16.
go back to reference Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells. Cancer Lett. 2005;223(1):1–10.CrossRef Givant-Horwitz V, Davidson B, Reich R. Laminin-induced signaling in tumor cells. Cancer Lett. 2005;223(1):1–10.CrossRef
17.
go back to reference Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol. 2003;200(4):465–70.CrossRef Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol. 2003;200(4):465–70.CrossRef
18.
go back to reference Lin Q, et al. Analysis of colorectal cancer glyco-secretome identifies laminin beta-1 (LAMB1) as a potential serological biomarker for colorectal cancer. Proteomics. 2015;15(22):3905–20.CrossRef Lin Q, et al. Analysis of colorectal cancer glyco-secretome identifies laminin beta-1 (LAMB1) as a potential serological biomarker for colorectal cancer. Proteomics. 2015;15(22):3905–20.CrossRef
19.
go back to reference Alinezhad S, et al. Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies. PLoS ONE. 2016;11(5):e0155901.CrossRef Alinezhad S, et al. Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies. PLoS ONE. 2016;11(5):e0155901.CrossRef
20.
go back to reference Angarica VE, Del Sol A. Bioinformatics tools for genome-wide epigenetic research. Adv Exp Med Biol. 2017;978:489–512.CrossRef Angarica VE, Del Sol A. Bioinformatics tools for genome-wide epigenetic research. Adv Exp Med Biol. 2017;978:489–512.CrossRef
21.
go back to reference Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5(10):588–99.CrossRef Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5(10):588–99.CrossRef
22.
go back to reference Senchenko VN, et al. Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer. Epigenetics. 2013;8(4):409–20.CrossRef Senchenko VN, et al. Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer. Epigenetics. 2013;8(4):409–20.CrossRef
23.
go back to reference Gerashchenko GV, et al. Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer. Ukr Biokhim Zh (1999). 2009;81(4):81–7. Gerashchenko GV, et al. Screening of epigenetic and genetic disturbances of human chromosome 3 genes in colorectal cancer. Ukr Biokhim Zh (1999). 2009;81(4):81–7.
24.
go back to reference Chen Q, et al. MiR-124-5p inhibits the growth of high-grade gliomas through posttranscriptional regulation of LAMB1. Neuro Oncol. 2014;16(5):637–51.CrossRef Chen Q, et al. MiR-124-5p inhibits the growth of high-grade gliomas through posttranscriptional regulation of LAMB1. Neuro Oncol. 2014;16(5):637–51.CrossRef
Metadata
Title
Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis
Authors
Yue Peng
Dong Wu
Fangmei Li
Peihua Zhang
Yuandong Feng
Aili He
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01355-z

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine